Phibro Animal Health Corp (Phibro), a subsidiary of BFI Co LLC, develops, manufactures, and commercializes products for food and companion animals, including poultry, swine, beef and dairy cattle, and aquaculture. The company markets approximately 800 product lines in about 90 countries, serving around 4,500 customers. It provides solutions to livestock producers, farmers, veterinarians, and consumers to maintain and enhance animal health. The company also manufactures and markets specific ingredients for use in the personal care, industrial chemical, and chemical catalyst industries. The company operates through three reportable business segments: Animal Health, Mineral Nutrition, and Performance Products. Phibro's sales organization includes over 520 employees and approximately 370 distributors, marketing its products in about 90 countries. Phibro operates manufacturing facilities in various locations, including Brazil, the United States, Italy, China, Israel, and Ireland.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

The company’s R&D efforts focus on product development, quality assurance, quality control and providing technical services to customers. It also aims at various services such as fermentation development and micro-biological strain improvement; vaccine development; chemical synthesis and formulation development; nutritional speciality product development; and ethanol-related products. The company is investing in next-generation vaccine technologies and microbial solutions that address animal health, nutrition challenges across diverse sectors, including environmental, industrial, and agricultural applications. The company operates Animal Health R&D and product testing at several of its domestic and international facilities. It also engages various independent contract research organizations for research and development activities. The company develops, manufactures, and markets microbial products and bioproducts. It has developed and markets approximately 50 product lines for the prevention of diseases in poultry, and also develops, manufactures, and markets autogenous vaccines against animal diseases. The company has developed TAbic, a patented technology for the formulation and delivery of vaccine antigens and continues to focus on innovation to produce new antigens or new presentations of antigens. In FY2025 the company spent US$23.7 million on its R&D activities, which as a percentage of revenue stood at 1.8% and decreased 18.7% YoY.